Microglial activation is raised in preclinical Alzheimer’s disease and associated with covert memory impairment

Key Points

• Impaired memory test performance is evident in preclinical Alzheimer's disease and is linked to microglial activation, raising concerns about early cognitive risks.
• In affected cases, raised microglial activation indicates underlying cognitive issues despite the absence of outward symptoms during assessment.
• Microglial activation was measured in preclinical Alzheimer's patients without cognitive complaints, highlighting a need for further understanding of early changes.
• These findings suggest potential strategies for early intervention in Alzheimer's disease, given the early signs of cognitive decline.